MYPT1 inhibits the metastasis of renal clear cell carcinoma via the MAPK8/N‐cadherin pathway
Qingling Xie,
Ren Liu,
Zhihao Zou,
Yuanfa Feng,
Yiqiao Huang,
Guibin Xu,
Wei Sun,
Yuxiang Liang,
Weide Zhong
Affiliations
Qingling Xie
Guangdong Provincial Institute of Nephrology, Nanfang Hospital Southern Medical University Guangzhou China
Ren Liu
Guangdong Provincial Institute of Nephrology, Nanfang Hospital Southern Medical University Guangzhou China
Zhihao Zou
Department of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, School of Medicine South China University of Technology Guangzhou China
Yuanfa Feng
Department of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, School of Medicine South China University of Technology Guangzhou China
Yiqiao Huang
Department of Urology The Fifth Affiliated Hospital of Guangzhou Medical University China
Guibin Xu
Department of Urology The Fifth Affiliated Hospital of Guangzhou Medical University China
Wei Sun
Department of Urology, Huadu District People's Hospital Southern Medical University Guangzhou China
Yuxiang Liang
Department of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, School of Medicine South China University of Technology Guangzhou China
Weide Zhong
Guangdong Provincial Institute of Nephrology, Nanfang Hospital Southern Medical University Guangzhou China
Myosin phosphatase target subunit 1 (MYPT1) is a subunit of myosin phosphatase that is capable of regulating smooth muscle contraction. MYPT1 has been reported to be involved in a wide variety of tumours, but its expression and biological functions in renal clear cell carcinoma (ccRCC) remain obscure. Herein, we analysed the relationship between patient clinicopathological characteristics and MYPT1 expression levels in ccRCC patients using a tissue microarray (TMA) and data retrieved from the TCGA‐KIRC dataset. MYPT1 was overexpressed or depleted using siRNA in ccRCC cells to assess the effects on migration and invasion in vitro and in vivo. Additionally, RNA‐sequencing and bioinformatics analysis were performed to investigate the precise mechanism. MYPT1 expression in ccRCC tissues was observed to be lower than that in nonmalignant tissues (P < 0.05). In addition, MYPT1 downregulation was closely linked to advanced pathological stage (P < 0.05), and poor OS (overall survival; P < 0.05). Functionally, increased expression of MYPT1 suppressed ccRCC migration and invasion in vitro, and inhibited tumour metastasis in vivo. In addition, MYPT1 overexpression exerted its suppressive effects via the MAPK8/N‐cadherin pathway in ccRCC.
